Pilexam

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pilexam

Quick Facts: Pilexam

Property Description
Active Ingredient Tranexamic Acid (TXA)
Pharmacological Class Antifibrinolytic Agent
Origin Synthetic (Lysine derivative)
Common Forms Tablet, Injection Solution
General Purpose Aids in controlling blood loss

Defining Pilexam: The Antifibrinolytic Hemostatic Agent

Pilexam is a prescription-only pharmaceutical preparation primarily classified as an antifibrinolytic agent. It is functionally a hemostatic agent because its general purpose is to aid the body in controlling blood loss and supporting clot stabilization. The drug is a single-ingredient product, with its essential action delivered by the core substance, Tranexamic Acid (INN: TXA).

Tranexamic acid belongs to a class of medications called antifibrinolytics, which help prevent the breakdown of blood clots. This indicates the medicine's fundamental role in protecting the body’s natural defense against blood loss, a mechanism utilized in situations involving excessive bleeding.


Composition, Origin, and Available Forms

The active ingredient in Pilexam is Tranexamic Acid (TXA), a synthetic compound specifically engineered as a derivative of the amino acid lysine. Its deliberate chemical design confirms its non-natural origin, providing a standardized and predictable pharmacological action. The substance is considered a crucial medicine for a basic healthcare system, reflecting its established global use.

Pilexam, typically available as an Rx-only tablet, is distinct in its systemic positioning for adults. It is also available in an injection solution (ampoule). This diversity of preparations means the drug can be administered both systemically (acting throughout the body) and, in some formulations, locally for focused application.


The General Purpose of Tranexamic Acid

The general purpose of Pilexam is to maintain the body's hemostatic defense by preventing the premature breakdown of blood clots. It achieves this by focusing on inhibition of fibrinolysis, the physiological process responsible for dissolving the fibrin matrix of a clot. This protective action ensures that once a clot is formed, it remains intact and durable long enough for the body’s natural repair mechanisms to progress, thereby aiding the overall control of blood loss.

Regulatory References

  1. Tranexamic Acid: MedlinePlus Drug Information
  2. Tranexamic acid - eEML

What side effects are possible with Pilexam?

Possible Side Effects and Safety Information

The regulatory profile for Pilexam (Tranexamic Acid) establishes a clear hierarchy of documented adverse reactions, which are classified by frequency and grouped into System Organ Classes (SOCs).


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on data documented in official regulatory sources:

  • Common: The most frequently documented effects, potentially affecting up to 1 in 10 people, are centered on Gastrointestinal Disorders and include nausea, vomiting, and diarrhea.
  • Uncommon: Effects affecting up to 1 in 100 people include allergic dermatitis and other hypersensitivity reactions.
  • Rare: Reactions affecting up to 1 in 1,000 people involve the Nervous System and Eye Disorders, specifically including convulsions and visual impairment (such as color vision defects).

Serious Safety Considerations and Restrictions

Official labeling defines specific serious risks and constraints:

Classification Detail System Organ Class
Serious Rare Risk Documented risk of thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism). Vascular Disorders
Administration Risk Hypotension (low blood pressure) may occur if the injection is administered too rapidly. Vascular Disorders
Population Note Patients with renal impairment face an increased risk of drug accumulation and associated adverse effects. Renal System

Tranexamic acid is formally contraindicated in patients with a history of thromboembolic disease, active clotting, or known hypersensitivity to the substance. These restrictions align with the need to carefully manage the medicine's core safety profile.

Overdose and Emergency Response

The official regulatory documentation describes overdose of Pilexam (Tranexamic Acid) as potentially involving common gastrointestinal disturbances, specifically nausea, vomiting, and diarrhea. Systemic effects may include dizziness, headache, and orthostatic symptoms such as hypotension or faintness. A suspected overdose mandates that the medication be discontinued immediately and that the individual seek immediate medical attention. This urgent action is critical due to the documented potential for severe outcomes, including convulsions (seizures) and the risk of thromboembolic events (blood clots) in the vascular system. These severe manifestations are explicitly noted in regulatory labeling. Management of an overdose is officially limited to symptomatic and supportive treatment, as government documents state that no specific antidote is known. Supportive procedures described in official guidance include gastric lavage and the administration of activated charcoal. Hospital monitoring may be required following a significant overdose, particularly in patients with impaired renal function, who face an increased risk of drug accumulation and associated toxicity.

Therapeutic Uses of Pilexam

What Pilexam Treats: Main Uses and Benefits

Pilexam is a medication generally used for managing symptoms related to physical discomfort and as an antipyretic (fever reducer). The core therapeutic domain is commonly used to help with the temporary relief of pain and the reduction of fever across a range of conditions involving episodic or fluctuating manifestations.

This medicine is commonly used to help with acute or fluctuating manifestations such as: headache (including migraine and tension headache), toothache, and muscular aches and pains. It may assist with discomfort during episodes, including rheumatic pain, period pain (dysmenorrhoea), and backache. This focus on symptomatic support is considered relevant in contexts involving heightened systemic burden.

“It supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.”

It also supports the body during conditions involving episodic or fluctuating manifestations like colds and flu by easing discomfort and helping to reduce a high temperature. This focus on comfort is relevant when supportive symptom management is appropriate.


Quick Fact: May help ease symptoms related to physical discomfort

Eligibility and Restrictions for Use

Population Eligibility and Restrictions

Pilexam (Tranexamic Acid) eligibility is strictly defined by regulatory bodies, primarily to mitigate vascular risk. The medicine is contraindicated and must not be used by patients with active thromboembolic disease (such as DVT or PE) or those with a history of retinal vessel occlusion. Absolute exclusion also applies to individuals with a known hypersensitivity to the drug or those with certain intrinsic conditions that increase the risk of clotting. Furthermore, use is contraindicated for women taking combined hormonal contraceptives due to the compounding risk of thromboembolic events.

Conditional Use and Limitations

Eligibility is restricted for patients with renal impairment (kidney function problems), necessitating a mandatory dose adjustment as dictated by official prescribing information. While the medicine is generally allowed for adults, its safety and efficacy have not been established in pediatric patients younger than 12 years of age for the oral form. For pregnant individuals, use is only permitted if the treating physician determines the potential benefit justifies the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes interactions with Pilexam that are officially documented in government regulatory labeling. The information is strictly descriptive and does not constitute medical advice.

Pharmacodynamic Interactions

The primary documented interactions involve medicines that affect the body’s blood clotting system:

  • Thrombolytic Agents: Concomitant use with medicines used to break down clots (thrombolytic agents) may result in a pharmacodynamic antagonism, meaning the effect of Pilexam may be reduced.
  • Other Antifibrinolytic Agents: Combining Pilexam with other antifibrinolytic medicines is a theoretical risk for additive effects due to their similar action on the clotting process.

Interaction-Related Constraints and Supervision

Certain combinations require specific precautions or professional oversight:

  • Hormonal Contraceptives: Use of Pilexam in individuals taking hormonal contraceptives requires caution due to a documented increased risk of thrombosis (blood clot formation).
  • Anticoagulants: When Pilexam is administered concurrently with medicines used to prevent blood clotting (anticoagulants), this treatment must proceed under the strict supervision of a physician experienced in this field.

Pharmacokinetic and General Interactions

Official regulatory documents state that no formal interaction studies have been performed to assess the effects of Pilexam on metabolic pathways, such as the cytochrome P450 (CYP) enzymes or drug transporters (e.g., P-gp). Therefore, no specific pharmacokinetic interactions or interactions with food, alcohol, or herbal products are documented in the labeling.

Mechanism of Action

Mechanism of Action: Antifibrinolytic Activity

Pilexam (Tranexamic Acid) works through a highly targeted mechanism focused on modulating the rate of dissolution of the pre-formed fibrin matrix. Its action is entirely antifibrinolytic, meaning it acts against the natural process of clot dissolution.


Targeting the Lysine Binding Sites (LBS) on Plasminogen

The drug's action begins at the molecular level by functioning as a competitive inhibitor against the inactive precursor molecule plasminogen. Being a synthetic derivative of lysine, Pilexam binds reversibly to the Lysine Binding Sites (LBS) on plasminogen. This interaction physically obstructs the sites that plasminogen uses to anchor itself to the fibrin network of a developing clot. The immediate physiological consequence of this binding is the inability of plasminogen to be correctly positioned and activated.


Blockade of the Fibrinolytic Cascade and Fibrin Preservation

By blocking the binding of plasminogen to the fibrin clot, Pilexam inhibits the conversion of plasminogen into the active clot-dissolving enzyme, plasmin. This suppression significantly attenuates the entire fibrinolytic pathway, which is responsible for cleaving and dissolving the fibrin scaffold. The resulting systemic effect is the reduced degradation of the fibrin matrix at the site of vascular injury, which maintains the physical integrity of the clot.

Dosage and Administration Information

Pilexam (Tranexamic Acid) is administered via two systemic routes: the oral route as a tablet and the intravenous (IV) route as an injection solution. The medicine is not for administration by the intramuscular or neuraxial routes.

The regimen for certain oral indications is typically 1300 mg per dose, taken three times daily, with a maximum daily intake of 3900 mg. The oral medication may be administered with or without food. The duration of this oral use is intermittent and time-bound, limited to a maximum of five days per cycle. Conversely, the intravenous dosing for acute systemic needs generally begins with a 1 gram or 15 mg/kg loading dose, followed by maintenance doses repeated every six to eight hours. The total duration of IV therapy is typically short-term.

Administration is subject to specific procedural constraints. Oral tablets must be swallowed whole and cannot be crushed or broken, maintaining the formulation's integrity. When administering the intravenous solution, the injection proceeds as a slow infusion, not exceeding a rate of 1 mL per minute. Furthermore, a dose adjustment is required for patients with renal impairment, with the modification based on the patient's calculated level of kidney function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pilexam

The research for the compound Tranexamic Acid (Pilexam’s active ingredient) provides context on how the compound was studied in research settings. The evidence base primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews, which help researchers understand how symptoms or physiological measures were recorded in the study groups.


Evidence for Use in Heavy Menstrual Bleeding

This section will summarize the design of the short-term randomized controlled trials and systematic reviews that explored the relationship between use of the compound and menstrual blood loss volume, and related outcomes reflecting daily functioning in adult women.

Studies reported consistent patterns observed in the measurements of MBL volume, with lower measured amounts of MBL reported in the group receiving the study compound compared to the control group over the defined time intervals. Research highlights data measured during the study period, including reports on patient-reported outcomes describing perceived discomfort. Long-term outcomes, including the durability of observed MBL changes or effects on gynecological health markers after the treatment period ends, are not well characterized.


Evidence for Use in Severe Hemorrhage and Trauma

This part will detail the structure of the large-scale trials and acute observational studies that explored the administration of the compound in populations experiencing major bleeding due to traumatic injury.

Studies reported data on bleeding-related mortality measurements. Trials described differences in the measured rate of bleeding-related death when the compound was administered within the first few hours after injury. Findings were mixed and appeared to be dependent on the timing of administration; some data describe differences in measured outcomes when the compound was administered late. The impact on functional and neurological recovery, especially in patients with severe head trauma, remains uncertain across all studied subgroups.


What is Still Uncertain About Pilexam

The evidence landscape, while extensive in areas like surgery, still presents key research limitations. Long-term effects and the durability of measured changes are not fully established across all uses. Findings were mixed for acute gastrointestinal bleeding, where large studies produced inconsistent results on outcomes like mortality, indicating that certainty remains low in this specific research context. Data for specific, high-risk patient subgroups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Pilexam (FAQ)


Q: Is Pilexam a type of antibiotic, or something else?

Pilexam is officially classified as an antifibrinolytic agent. This means its core function is to modulate the rate at which blood clots dissolve, which helps in controlling blood loss.

It is not an antibiotic, which is a class of medicine used specifically to fight bacterial infection.


Q: Are there any major diet restrictions when taking Pilexam?

According to the official product information, the oral tablet may be administered with or without food.

Regulatory labeling does not document any specific major food interactions that require restrictions while taking this medicine.


Q: Does alcohol interact negatively with Pilexam?

Regulatory labeling states that formal interaction studies to assess the effects of Pilexam with alcohol were not performed.

Therefore, no specific interactions with alcohol are documented in the official product information.


Q: What happens if I miss a dose of Pilexam?

Official instructions indicate that if a dose is missed, it is typically skipped. The next dose is then taken at the regularly scheduled time.

Official instructions typically state not to take two doses at once to make up for a missed dose.


Q: Is Pilexam generally safe for elderly patients?

Official documents do not typically specify a dedicated dosage adjustment based only on age for the elderly population.

However, it is noted that age-related decline in kidney function is common, and regulatory guidance specifies that dosage adjustments are required based on the patient's calculated kidney function.


Q: Can children or adolescents use Pilexam?

According to regulatory documents, the safety and efficacy of the oral form have not been established in pediatric patients younger than 12 years of age.

The eligibility for use in older adolescents is described by the specific formulation and indication listed in the product label.


Q: Are there any known issues combining Pilexam with supplements?

Official labeling states that no formal interaction studies have been performed to assess effects on metabolic pathways or drug transporters.

Because formal studies were not performed, the regulatory labeling does not document specific interactions with herbal products.


Q: Are there any official warnings about driving or operating machinery while on Pilexam?

Official regulatory documents list rare side effects involving the nervous system and eye disorders, such as visual impairment and convulsions.

A general caution is often included, indicating that tasks requiring high mental alertness, such as driving, may be affected if these side effects occur.


Q: Does Pilexam contain gluten, lactose, or common allergens?

Official labeling provides a full list of excipients, which are the inactive ingredients in the tablet or solution.

These lists include common fillers like lactose or gluten, and the information is available in the Description section of the regulatory documents.


Q: What are the official sources saying about the safety of Pilexam?

Factual information regarding the medicine's safety, side effects, and eligibility is published by government health authorities worldwide.

These official sources include bodies such as the FDA, the EMA, Health Canada, the MHRA, and the NIH (MedlinePlus/DailyMed).


Q: Can Pilexam interact with birth control pills?

Official documents state that the use of Pilexam is contraindicated for individuals taking combined hormonal contraceptives.

This means the medicine is not allowed to be used in this population due to a documented increased risk of developing blood clots (thrombosis).


Q: How long does Pilexam stay in your system?

Regulatory documents define the medicine's half-life, which describes how long it takes for the amount of drug in the body to be reduced by half.

The half-life for the active compound is typically cited in pharmacokinetic studies as approximately two hours.


Q: Is Pilexam considered a controlled substance?

Pilexam (Tranexamic Acid) is a prescription medicine but is not classified as a federally controlled substance by government authorities in the United States or similar agencies internationally.


Q: What should I do if I accidentally take too much Pilexam?

Official documents include a section on overdosage, which describes possible signs such as dizziness or low blood pressure.

Regulatory guidance describes that the treatment administered is generally supportive.


Q: Is it necessary to finish the full course of Pilexam if I feel better?

Official instructions indicate that the full prescribed regimen is intended to be completed, even if symptoms begin to improve quickly.

This ensures that the medicine provides its intended therapeutic effect over the defined time interval.


Q: Is there a specific lab test needed before starting Pilexam?

Official documents describe that an assessment of a patient’s kidney function (renal impairment) is required before the medicine is started, which requires a lab test.

Regular eye examinations are also noted as important for patients who may be using the medicine over a longer period.


Q: How long do patients typically take Pilexam?

The regulatory label specifies the approved duration for which the medicine should be taken.

For certain oral indications, the treatment is strictly limited to a maximum of five days per cycle, while intravenous therapy is generally short-term.


Q: Is Pilexam prescribed for pain management?

Pilexam is officially indicated as an antifibrinolytic agent to aid in the control of blood loss and support clot stabilization.

It is not listed in regulatory documents as a prescription treatment for pain management.


Q: Does Pilexam contain any ingredients that are known to be addictive?

The active ingredient is not chemically related to substances that are known for having addictive potential.

Furthermore, regulatory agencies do not classify Pilexam as a controlled substance.


Q: Can Pilexam make you feel tired or drowsy?

Official regulatory documents list adverse reactions that affect the Nervous System.

Documented effects in this category may include dizziness or somnolence (drowsiness).


Q: Does Pilexam cause hair loss?

Hair loss is not included in the official regulatory profile among the commonly, uncommonly, or rarely reported adverse reactions documented in the official safety profiles.

The regulatory profile establishes a clear hierarchy of documented side effects based on frequency.


Q: Is Pilexam known to cause weight gain or loss?

Weight gain or loss is not included in the official regulatory profile among the commonly, uncommonly, or rarely reported adverse reactions.

These adverse reactions are classified by frequency in regulatory labeling.


Q: Does Pilexam affect sleep patterns?

Regulatory documents list adverse reactions that belong to the Nervous System disorders category.

These types of documented effects may include somnolence or other effects that could impact sleep.


Q: Can Pilexam affect blood pressure readings?

Official documents warn that hypotension, or low blood pressure, is a documented administration risk.

This is noted specifically if the intravenous solution is administered at a rate that is too rapid.


Q: Is it normal to feel a change in appetite while on Pilexam?

Gastrointestinal disorders are classified as common adverse reactions, frequently including symptoms such as nausea, vomiting, and diarrhea.

Changes in appetite are sometimes reported as part of general gastrointestinal changes.


Q: Do people often experience dizziness or lightheadedness on Pilexam?

Official regulatory documents list adverse reactions that affect the Nervous System.

These effects may include feeling dizzy or lightheaded, though their exact frequency is determined by the specific classification in the regulatory label.


Q: Are there any official studies looking into Pilexam's effectiveness in women versus men?

Regulatory documents include a 'Use in Specific Populations' section, which summarizes clinical study data.

This section details if demographic differences, such as those between women and men, were analyzed during the clinical trials.


Q: Are there any reports of drug dependence with Pilexam?

According to official regulatory documents and classification systems, Pilexam is not reported or classified as a drug associated with the risk of dependence.

How should Pilexam be stored and disposed of?

How to Store and Dispose of Pilexam

Official regulatory documents define strict requirements for the storage, handling, and disposal of Pilexam (tranexamic acid solution for injection).

Storage and Stability Requirements

Condition Requirement Details
Unopened Storage Store below 25 C The product has a shelf-life of 3 years.
Stability After Dilution Use immediately, or store for 24 hours Chemical and physical stability is demonstrated for 24 hours at 25 C.
Handling (Microbial Safety) Store between 2 C and 8 C (refrigerated) If the product is not used immediately after dilution, storage must not exceed 24 hours in the refrigerator, unless prepared under controlled aseptic conditions.

Disposal Instructions

Any unused medicinal product or waste material, including used containers, must be disposed of in accordance with local requirements. No specific environmental or hazardous-waste instructions beyond compliance with local rules are documented in the official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pilexam found in:

A-Z Index: